A practical reference on lyophilized peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-25 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
=== Josh Thomas and Lachlan Keeffe === Lachlan Keeffe (drafted to Collingwood in 2008) and Josh Thomas (drafted to Collingwood in 2009) are the most recent players to breach the anti-doping code. They both tested positive for clenbuterol which led to a 2-year ban as well as a $50,000 fine. The banned substance was detected in their systems after taking illicit drugs during a night out. Both players were banned from playing AFL for 2 years and were delisted by the Collingwood Football Club, before being redrafted by Collingwood in the 2016 Rookie Draft.
=== DSF-GTP === The DSF-GTP (GFP-Tagged Protein-of-Interest) technique was developed by a team led by Patrick Schaeffer at James Cook University and published in Moreau et al. 2012. The development of differential scanning fluorimetry and the high-throughput capability of Thermofluor have vastly facilitated the screening of crystallization conditions of proteins and large mutant libraries in structural genomics programs, as well as ligands in drug discovery and functional genomics programs. These techniques are limited by their requirement for both highly purified proteins and solvatochromic dyes, prompting the need for more robust high-throughput technologies that can be used with crude protein samples. This need was met with the development of a new high-throughput technology for the quantitative determination of protein stability and ligand binding by differential scanning fluorimetry of proteins tagged with green fluorescent protein (GFP). This technology is based on the principle that a change in the proximal environment of GFP, such as unfolding and aggregation of the protein of interest, is measurable through its effect on the fluorescence of the fluorophore. The technology is simple, fast and insensitive to variations in sample volumes, and the useful temperature and pH range is 30–80 °C and 5–11 respectively. The system does not require solvatochromic dyes, reducing the risk of interferences. The protein samples are simply mixed with the test conditions in a 96-well plate and subjected to a melt-curve protocol using a real-time thermal cycler.
=== Cancer biology === With technological advances, this assay is becoming very beneficial especially in the cancer biology realm. A study was performed to better understand the role that claudin-7, a family of tight junction proteins, plays in cell migration in a type of human lung cancer cells. Due to the slower migration rate of claudin-7 knockdown cells, it supports the idea that this protein is important in cell migration an cell's ability to metastasize. Cells undergo sheet migration due to a multitude of signals and mechanisms when trying to close a wound, which is believed to be similar to the underlying mechanisms involved in metastasis.
Sources: en.wikipedia.org
=== Testosterone === A 2021 systemic review of studies found that "the current body of evidence does not indicate that creatine supplementation increases total testosterone, free testosterone, DHT or causes hair loss/baldness".
In 1910, Hahn was appointed professor by the Prussian Minister of Culture and Education, August von Trott zu Solz. Two years later, Hahn became head of the Radioactivity Department of the newly founded Kaiser Wilhelm Institute for Chemistry (KWIC) in Berlin-Dahlem (in what is today the Hahn-Meitner-Building of the Free University of Berlin). This came with an annual salary of 5,000 marks (equivalent to €29,000 in 2021). In addition, he received 66,000 marks in 1914 (equivalent to €369,000 in 2021) from Knöfler for the mesothorium process, of which he gave 10 per cent to Meitner. The new institute was inaugurated on 23 October 1912 in a ceremony presided over by Kaiser Wilhelm II. The Kaiser was shown glowing radioactive substances in a dark room. The move to new accommodation was fortuitous, as the wood shop had become heavily contaminated by radioactive liquids that had been spilt, and radioactive gases that had vented and then decayed and settled as radioactive dust, making sensitive measurements impossible. To ensure that their clean new laboratories stayed that way, Hahn and Meitner instituted strict procedures. Chemical and physical measurements were conducted in different rooms, people handling radioactive substances had to follow protocols that included not shaking hands, and rolls of toilet paper were hung next to every telephone and door handle. Strongly radioactive substances were stored in the old wood shop, and later in a purpose-built radium house on the institute grounds.
Back in the night, James meets with Grace as per her instructions and she asks James to forsake his Shadowhunter blood, run away, and marry her. It’s the only way she can escape her cruel mother. James silently considers it but decides there’s no way he can forsake his family, friends, or parabatai. Grace is angry at his declaration, but she’s cut short when demons attack them. Lucie, Christopher, Matthew, Thomas, Cordelia and Alastair come to their aid. The strongest demon recognizes James and asks why James is fighting against the creatures who worship his own grandfather. The demon calls Tessa’s demon father a prince of hell, which is a fallen angel as powerful as Raziel. James is shocked at the revelation. He lets the remaining demons go in the name of his grandfather as long as they go back to their own dimension. They will do so as long as no one present tells any other Shadowhunters about what transpired at the waterfront. After they’re gone, Tatiana pulls up in her carriage searching for Grace. James begs Grace to come to the Institute with him. His father will grant her safe haven. Tatiana promises to produce evidence to ruin Grace's reputation if she doesn’t come home with her. Ragnor visits the teenagers-sans Cordelia and Alastair, and gives them a lead - Emmanuel Gast, who he thought might be able to dredge up information. Shocking news arrives when Barbara Lightwood is pronounced dead. At the Carstairs manor in Cornwall Gardens, Charles visits late at night.
Sources: en.wikipedia.org
The terms "active" and "passive" are simple but important terms in the world of automotive safety. "Active safety" is used to refer to technology assisting in the prevention of a crash and "passive safety" to components of the vehicle (primarily airbags, seatbelts and the physical structure of the vehicle) that help to protect occupants during a crash. Crash avoidance systems and devices help the driver — and, increasingly, help the vehicle itself — to avoid a collision. This category includes: The vehicle's headlamps, reflectors, and other lights and signals The vehicle's mirrors The vehicle's brakes, steering, and suspension systems A subset of crash avoidance is driver assistance systems, which help the driver to detect obstacles and to control the vehicle. Driver assistance systems include:
Stanford dedicated the BIL gate's design to the public domain, which may speed its adoption. According to Endy, other researchers were already using the gates to reprogram metabolism when the Stanford team published its research. Computing by transcriptor is still very slow; it can take a few hours between receiving an input signal and generating an output. Endy doubted that biocomputers would ever be as fast as traditional computers, but added that is not the goal of his research. "We're building computers that will operate in a place where your cellphone isn't going to work", he said. Medical devices with built-in biological computers could monitor, or even alter, cell behavior from inside a patient's body. ExtremeTech writes:
Chemokine (C-C motif) ligand 7 (CCL7) is a small cytokine that was previously called monocyte-chemotactic protein 3 (MCP3). CCL7 is a small protein that belongs to the CC chemokine family and is most closely related to CCL2 (previously called MCP1). In the human genome, CCL7 is encoded by the CCL7 gene which is one of the several chemokine genes clustered on chromosome 17q11.2-q12. This region contains the gene for the MCP subset of CC chemokines. The CCL7 gene has been given the locus symbol SCYA7. The gene consists of three exons and two introns. The first exon contains a 5′-untranslated region (5′-UTR), the information for the signal sequence (23 amino acids), and the mature protein's first two amino acids. The second exon encodes amino acids 3–42 of the mature proteins. The third exon is composed of the C-terminal region of the protein, a 3′-UTR containing one or more destabilizing AU-rich sequences and a polyadenylation signal.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.